BioSpace News Archive

BBK Worldwide (BBK), the patient experience, recruitment, and engagement leader, today announced that Principal and Director of Accounts and Site Services, David B. Fleishman, was named one of the 100 most inspiring people in life sciences by PharmaVOICE magazine

Commenced enrollment of 8 patients into an ASPIRO pivotal expansion cohort to confirm the safety and efficacy profile of AT132 for the treatment of X-linked myotubular myopathy (XLMTM) at dose of 3x10

Inovio Intends to Pursue Secondary Listing on Korea Exchange (KRX)

Revenue of $134.2 million in the second quarter of 2019, an increase of 22.4%, or 23.8% in constant currency1, over the second quarter of 2018.

Joseph J. Ferra will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference. Details are as follows:

Total Revenues Increased 7% to $534 Million

Second quarter 2019 revenue of $19.3 million, an increase of 102% over prior year period

Cash and marketable securities totaled $389.2 million at June 30, 2019

Gencurix, Inc., a company dedicated in development and market of innovative molecular diagnostics, announced the publication of a new study onFrontiers in Oncology comparing GenesWell™ BCT, a prognostic multigene test, with Genomic Health’s Oncotype DX in patients with early-stage breast cancer

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today reported financial results for the second quarter ended June 30, 2019 and provided a review of recent business and clinical highlights.